Exemestane

Generic Name: Exemestane

Brand Names: Aromasin

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₄O_₂

CAS Number: 107868-30-4

Unique Ingredient Identifier: NY22HMQ4BX

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Background: Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.

Indication: For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Associated Conditions: Stage I Breast Cancer, Refractory, advanced Breast cancer

Clinical Trials

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Phase 2

Not yet recruiting

Conditions: Malignant Neoplasm

Interventions: Drug: Megestrol acetate/Medroxyprogesterone acetate
Drug: MK-5684
Drug: Fulvestrant
Drug: Tamoxifen
Drug: Fludrocortisone/ Fludrocortisone acetate
Drug: Exemestane
Drug: Letrozole
Drug: Dexamethasone/Dexamethasone acetate
Drug: Rescue Medications

First Posted Date: 2025-05-20

Last Posted Date: 2025-05-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 250

Registration Number: NCT06979596

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Phase 2

Active, not recruiting

Conditions: HR+/HER2- Advanced/Metastatic Breast Cancer

Interventions: Drug: Letrozole
Drug: Anastrozole
Drug: Exemestane
Drug: Fulvestrant
Drug: Sirolimus for Injection (Albumin-bound)

First Posted Date: 2025-05-04

Last Posted Date: 2025-05-04

Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 78

Registration Number: NCT06957379

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE)

Phase 3

Recruiting

Conditions: Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: Everolimus (Afinitor®)
Drug: SIM0270
Drug: Exemestane tablets
Drug: Fulvestrant injection

First Posted Date: 2024-11-08

Last Posted Date: 2024-12-04

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 460

Registration Number: NCT06680921

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial

Phase 3

Recruiting

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8
Anatomic Stage 1 Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Estrogen Receptor-Positive Breast Carcinoma
HER2-Negative Breast Carcinoma

Interventions: Drug: Tamoxifen
Drug: Anastrozole
Procedure: Mammogram
Drug: Letrozole
Drug: Exemestane
Procedure: Magnetic Resonance Imaging
Biological: Dual X-ray Absorptiometry
Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2024-11-04

Last Posted Date: 2025-04-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 1156

Registration Number: NCT06671912

Locations: 🇺🇸
Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States
🇺🇸
Keck Medicine of USC Buena Park, Buena Park, California, United States
🇺🇸
Enloe Medical Center, Chico, California, United States

and more 110 locations

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients with Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Advanced Breast Carcinoma
Advanced Malignant Solid Neoplasm
Advanced Ovarian Carcinoma
Advanced Pancreatic Carcinoma
Advanced Prostate Carcinoma
Advanced Sarcoma
Anatomic Stage III Breast Cancer AJCC V8
Anatomic Stage IV Breast Cancer AJCC V8
Stage III Ovarian Cancer AJCC V8
Stage III Pancreatic Cancer AJCC V8

Interventions: Drug: Abemaciclib
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Fulvestrant
Procedure: Bone Scan
Drug: Carboplatin
Drug: Olaparib
Procedure: Echocardiography
Drug: Gemcitabine
Drug: Pemetrexed
Drug: Exemestane
Drug: Letrozole
Drug: Gefitinib
Procedure: Multigated Acquisition Scan
Other: Survey Administration
Drug: Tamoxifen
Drug: Temozolomide
Drug: Paclitaxel
Drug: Osimertinib
Drug: Pegylated Liposomal Doxorubicin Hydrochloride

First Posted Date: 2024-10-08

Last Posted Date: 2025-02-13

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 30

Registration Number: NCT06630325

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Elacestrant
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane
Drug: Tamoxifen

First Posted Date: 2024-07-09

Last Posted Date: 2025-05-21

Lead Sponsor: Stemline Therapeutics, Inc.

Target Recruit Count: 4220

Registration Number: NCT06492616

Locations: 🇪🇸
Hospital Beata Maria Ana, Madrid, Spain
🇺🇸
Southern Cancer Center, PC, Daphne, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 169 locations

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Belzutifan
Drug: Everolimus
Drug: Fulvestrant
Drug: Exemestane

First Posted Date: 2024-05-24

Last Posted Date: 2025-05-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 120

Registration Number: NCT06428396

Locations: 🇨🇴
IMAT S.A.S ( Site 1205), Monteria, Cordoba, Colombia
🇨🇦
Jewish General Hospital ( Site 0400), Montreal, Quebec, Canada
🇬🇧
Ipswich Hospital ( Site 1911), Ipswich, Suffolk, United Kingdom

and more 29 locations